Press release
Compass Therapeutics to Present at Upcoming Investment Conferences
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary
About this update from Compass Therapeutics, Inc.
[{"type":"text","content":"BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during the month of November 2022. Presentation details are as follows: Stifel Healthcare Conference in New York City Date: Tuesday, November 15, 2022Time: 4:10-4:40 PM ETWebcast Link: https://wsw.com/webcast/stifel74/cmpx/2109872 Jefferies Global Healthcare Conference in London, UK Date: Wednesday, November 16, 2022Time: 3:15 – 3:45 PM GMTWebcast Link: https://wsw.com/webcast/jeff255/cmpx/1866024 Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page. About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com. Investor ContactMario Corso, Executive Director and Head of Investor [email protected] Media ContactAnna Gifford, Communications [email protected] 617-500-8099 \nSource: Compass Therapeutics","length":5320,"tagName":"div"}]